自引率: 6.6%
被引量: 7723
通过率: 暂无数据
审稿周期: 2
版面费用: 暂无数据
国人发稿量: 6
投稿须知/期刊简介:
The aim of Maturitas is to provide a critical medium for the exchange of information and ideas concerning the important changes in many physiological, psychological and sociological functions, occurring in the middle years and beyond, as far as related to the climacteric in both men and women.Maturitas will publish original research papers in the following areas: Studies in anatomy, endocrinology, gynaecology, andrology, biochemistry, pharmacology, physiology, pathology, psychology, epidemiology, sociology, sexology and other disciplines on topics concerned with the middle years and beyond, as far as related to the climacteric including relevant animal studies Related clinical case studies Management, prevention and therapeutic problems related to ageing and to the climacteric in men and women Other relevant material at the discretion of the Chief Editor
期刊描述简介:
The aim of Maturitas is to provide a critical medium for the exchange of information and ideas concerning the important changes in many physiological, psychological and sociological functions, occurring in the middle years and beyond, as far as related to the climacteric in both men and women.Maturitas will publish original research papers in the following areas: Studies in anatomy, endocrinology, gynaecology, andrology, biochemistry, pharmacology, physiology, pathology, psychology, epidemiology, sociology, sexology and other disciplines on topics concerned with the middle years and beyond, as far as related to the climacteric including relevant animal studies Related clinical case studies Management, prevention and therapeutic problems related to ageing and to the climacteric in men and women Other relevant material at the discretion of the Chief Editor
-
Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women.
To compare menopausal symptoms of breast cancer survivors on adjuvant endocrine therapy with those of menopausal women. In a retrospective nested case-control study menopausal symptoms were compared of breast cancer survivors in pre-, peri- or post-menopause at the time of diagnosis, on tamoxifen or an aromatase inhibitor, plus a gonadotrophin-releasing hormone analogue, if pre- or peri-menopausal, and age-matched control women either in the late peri-menopause, or in surgical or in physiological post-menopause on no hormone replacement therapy. Differences between women on tamoxifen and those on aromatase inhibitors were also evaluated. Weighted and non-weighted t-tests, chi-square tests, and linear or logistic regressions were applied as appropriate. Score on the Greene's Climacteric Scale and so of its subscales evaluating vasomotor, anxiety, depression, somatisation and sexuality symptoms. A total of 99 breast cancer survivors (45 on tamoxifen, 54 on aromatase inhibitors) and 554 controls (173 in late perimenopause, 353 in natural and 28 in surgical menopause) were enrolled. The score on the Greene's Climacteric Scale was similar in cases and controls (means ± standard deviation) (21.3 ± 10.4 vs. 22.8 ± 11.5, p = 0.199), as were the subscale scores for vasomotor symptoms, anxiety, and somatisation. The depression score was lower (4.63 ± 3.3 vs. 5.98 ± 3.8; p = 0.001) in breast cancer survivors on adjuvant endocrine therapy, mainly due to a lower score of -2.132 (95 % confidence interval - 3.858/-0.407; p = 0.016) for users of aromatase inhibitors. The sexuality score was higher (1.76 ± 1.1 vs. 1.50 ± 1.1, p = 0.011) than in controls. Differences remained significant when corrected for age, menarche, body mass index, menopausal status (peri- or post-), type of menopause (natural, surgical), use of gonadotrophin-releasing hormone analogues, years of amenorrhea, smoking, alcohol use, and for breast radiotherapy, chemotherapy, tamoxifen or aromatase inhibitors. Among breast cancer survivors, women on aromatase inhibitors had lower scores for anxiety (5.75 ± 2.5vs.5.75 ± 2.5; p = 0.045) and depression (3.89 ± 2.5 vs. 5.13 ± 3.6; p = 0.046) than women on tamoxifen. In breast cancer survivors, adjuvant therapy induces symptoms similar in type and intensity to those of symptomatic menopausal women. Compared with menopausal women, breast cancer survivors, particularly those on aromatase inhibitors, appear to experience less severe depressive symptoms.
被引量：- 发表：1970
-
Protective and harmful social and psychological factors associated with mood and anxiety disorders in perimenopausal women: A narrative review.
被引量：- 发表：1970
-
Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population.
被引量：- 发表：1970
-
Prevalence and impact of vasomotor symptoms associated with menopause among women in Brazil: Subgroup analysis from an international cross-sectional survey.
被引量：- 发表：1970
-
Validation of the efficacy of a personalized information-provision and exercise-coaching app on the quality of life of menopausal women.
被引量：- 发表：1970
